Notice of Appeal

Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

NICE has received 1 appeal that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:

• Eli Lilly and Company Limited

The appeal panel will convene on Wednesday 22 October 2025 at 10:00am via Zoom to hear oral representations from the appellant.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

Where possible, requests to attend should be made using the registration link that will be available on our website from 15 July 2025. The registration period for this appeal will end at 4:00pm on Wednesday 15 October 2025

Further details relating to public attendance at this appeal are available on the same webpage as above.